TWI749016B - 具有奇數碳的脂類化合物及其作為醫藥組合物或者營養補充劑的用途 - Google Patents

具有奇數碳的脂類化合物及其作為醫藥組合物或者營養補充劑的用途 Download PDF

Info

Publication number
TWI749016B
TWI749016B TW106118787A TW106118787A TWI749016B TW I749016 B TWI749016 B TW I749016B TW 106118787 A TW106118787 A TW 106118787A TW 106118787 A TW106118787 A TW 106118787A TW I749016 B TWI749016 B TW I749016B
Authority
TW
Taiwan
Prior art keywords
day
aβo
compound
diseases
hours
Prior art date
Application number
TW106118787A
Other languages
English (en)
Chinese (zh)
Other versions
TW201801720A (zh
Inventor
董宇紅
張俊雄
Original Assignee
董宇紅
張俊雄
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 董宇紅, 張俊雄 filed Critical 董宇紅
Publication of TW201801720A publication Critical patent/TW201801720A/zh
Application granted granted Critical
Publication of TWI749016B publication Critical patent/TWI749016B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
TW106118787A 2016-06-08 2017-06-06 具有奇數碳的脂類化合物及其作為醫藥組合物或者營養補充劑的用途 TWI749016B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08
US62/347,103 2016-06-08

Publications (2)

Publication Number Publication Date
TW201801720A TW201801720A (zh) 2018-01-16
TWI749016B true TWI749016B (zh) 2021-12-11

Family

ID=60577583

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106118787A TWI749016B (zh) 2016-06-08 2017-06-06 具有奇數碳的脂類化合物及其作為醫藥組合物或者營養補充劑的用途

Country Status (12)

Country Link
US (2) US11406616B2 (enExample)
EP (1) EP3468551A4 (enExample)
JP (2) JP6872805B2 (enExample)
KR (1) KR20190017873A (enExample)
CN (2) CN117298092A (enExample)
AU (1) AU2017277005B2 (enExample)
CL (1) CL2018003537A1 (enExample)
MX (1) MX2018015188A (enExample)
NZ (1) NZ749389A (enExample)
SG (1) SG11201810580PA (enExample)
TW (1) TWI749016B (enExample)
WO (1) WO2017211274A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
WO2021107084A1 (ja) * 2019-11-27 2021-06-03 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
JP2024523429A (ja) * 2021-06-18 2024-06-28 サンレーゲン ヘルスケア エージー ウイルス感染の神経学的合併症の処置と予防のための新規化合物
JP7898267B2 (ja) * 2021-10-20 2026-07-31 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
WO2024075625A1 (ja) * 2022-10-02 2024-04-11 リファインホールディングス株式会社 視野欠損障害、光誘発眼組織障害およびその関連障害の予防剤、進行防止剤、改善剤、並びに食品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1514723A (zh) * 2001-04-11 2004-07-21 Ү���о�����չ���޹�˾ 用于治疗炎症的脂肪醇和脂肪酸酯
US20070123588A1 (en) * 2003-05-20 2007-05-31 Charles Roe R Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
KR100829729B1 (ko) * 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
CN102781438A (zh) * 2009-12-30 2012-11-14 贝勒研究院 用于阿尔茨海默病和脑衰老的补给疗法
CN103641713A (zh) * 2013-11-15 2014-03-19 浙江大学 甘油单酯衍生物的制备方法及应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
CA1244772A (en) 1983-06-21 1988-11-15 Kuniaki Adachi Cell-stimulating composition
JPH02247125A (ja) 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2752800T3 (es) 2000-05-01 2020-04-06 Cerecin Inc Uso de triglicéridos de cadena media para el tratamiento y la prevención de la enfermedad del Parkinson resultante de un metabolismo neuronal reducido
DE60123603T2 (de) 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
DK1900364T3 (da) 2001-04-18 2014-01-13 Prometic Biosciences Inc Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
EP2324828A1 (en) 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
JP4334956B2 (ja) 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
JP2011502950A (ja) 2006-09-26 2011-01-27 ベイラー リサーチ インスティテュート 栄養センサー
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
US9532962B2 (en) 2007-11-02 2017-01-03 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
AU2011204277B2 (en) * 2010-01-08 2015-12-24 Catabasis Pharmaceuticals, Inc. Fatty Acid Fumarate Derivatives and their uses
US20130196937A1 (en) * 2010-02-10 2013-08-01 Oryza Oil & Fat Chemical Co., Ltd. Age production inhibitor
US20110301238A1 (en) 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
MX2012014520A (es) 2010-06-14 2013-03-05 Baylor Res Inst Dieta de triheptanoina para tratamiento de enfermedad del cuerpo de poliglucosano (apbd).
AU2011278346B2 (en) * 2010-07-15 2016-04-07 Hybrigenics Sa New formulations of 14 - epi -analogues of vitamin D
US9393224B2 (en) 2011-08-26 2016-07-19 Osaka University Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
CN102526643B (zh) * 2012-03-22 2013-09-11 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
AU2013358951C1 (en) 2012-12-13 2019-06-27 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
CN117502539A (zh) * 2013-08-02 2024-02-06 施韦特-莫迪国际公司 包含经重构植物材料的可食用产品
AU2014348457B2 (en) 2013-11-14 2019-04-18 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CN105381182A (zh) * 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用
WO2017093060A1 (en) 2015-12-04 2017-06-08 Nestec S.A. Method for improving cognition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1514723A (zh) * 2001-04-11 2004-07-21 Ү���о�����չ���޹�˾ 用于治疗炎症的脂肪醇和脂肪酸酯
US20070123588A1 (en) * 2003-05-20 2007-05-31 Charles Roe R Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
KR100829729B1 (ko) * 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
CN102781438A (zh) * 2009-12-30 2012-11-14 贝勒研究院 用于阿尔茨海默病和脑衰老的补给疗法
CN103641713A (zh) * 2013-11-15 2014-03-19 浙江大学 甘油单酯衍生物的制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
張幗威，狹葉瓶爾小草化學成分的研究，西南交通大學研究生學位論文，第1-58頁，2008年5月 *
張幗威，狹葉瓶爾小草化學成分的研究，西南交通大學研究生學位論文，第1-58頁，2008年5月。

Also Published As

Publication number Publication date
KR20190017873A (ko) 2019-02-20
US20190255129A1 (en) 2019-08-22
JP2019518034A (ja) 2019-06-27
JP2021113204A (ja) 2021-08-05
CN117298092A (zh) 2023-12-29
NZ749389A (en) 2022-12-23
CL2018003537A1 (es) 2019-05-03
CN110300581A (zh) 2019-10-01
MX2018015188A (es) 2019-08-21
US12594255B2 (en) 2026-04-07
US11406616B2 (en) 2022-08-09
JP6872805B2 (ja) 2021-05-19
EP3468551A1 (en) 2019-04-17
AU2017277005A1 (en) 2019-01-17
EP3468551A4 (en) 2020-01-22
CN110300581B (zh) 2023-09-08
SG11201810580PA (en) 2018-12-28
AU2017277005B2 (en) 2022-12-22
TW201801720A (zh) 2018-01-16
CA3026152A1 (en) 2017-12-14
WO2017211274A1 (en) 2017-12-14
US20220362197A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US12594255B2 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
US11510887B2 (en) Sobetirome in the treatment of myelination diseases
CN112566641A (zh) 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物
RS67601B1 (sr) Terapijski agensi za upotrebu u lečenju sindroma nemirnih nogu
WO2023034115A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
CA3026770C (en) Andrographolide treats progressive forms of multiple sclerosis
CA3026152C (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2019052629A1 (en) LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
JP5200347B2 (ja) 眼精疲労の予防又は緩和剤
EP3273978A1 (en) Use of a withania extract for the treatment of amyloid-related diseases
HK40021759B (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP5417727B2 (ja) 網膜保護剤
HK40021759A (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
TWI855694B (zh) 丹參莖葉萃取物用於製備眼睛視覺保健及/或預防、改善眼疾、功能性視覺及/或高度近視視覺保健之組合物的用途
TW202103679A (zh) 一種落葵萃取物用於製備預防或治療神經系統疾病組合物的用途
Navarrete-Opazo et al. Articles in PresS. Am J Physiol Regul Integr Comp Physiol (September 17, 2014). doi: 10.1152/ajpregu. 00208.2014
HK1222552B (en) Sobetirome in the treatment of myelination diseases